According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...